568 related articles for article (PubMed ID: 15735809)
1. Changes in ADAMTS13 (von-Willebrand-factor-cleaving protease) activity after induced release of von Willebrand factor during acute systemic inflammation.
Reiter RA; Varadi K; Turecek PL; Jilma B; Knöbl P
Thromb Haemost; 2005 Mar; 93(3):554-8. PubMed ID: 15735809
[TBL] [Abstract][Full Text] [Related]
2. Changes in von Willebrand factor-cleaving protease (ADAMTS13) activity after infusion of desmopressin.
Reiter RA; Knöbl P; Varadi K; Turecek PL
Blood; 2003 Feb; 101(3):946-8. PubMed ID: 12393734
[TBL] [Abstract][Full Text] [Related]
3. Imbalance of von Willebrand factor and its cleaving protease ADAMTS13 during systemic inflammation superimposed on advanced cirrhosis.
Reuken PA; Kussmann A; Kiehntopf M; Budde U; Stallmach A; Claus RA; Bruns T
Liver Int; 2015 Jan; 35(1):37-45. PubMed ID: 25113276
[TBL] [Abstract][Full Text] [Related]
4. Increased plasma von Willebrand factor antigen levels but normal von Willebrand factor cleaving protease (ADAMTS13) activity in preeclampsia.
Molvarec A; Rigó J; Bõze T; Derzsy Z; Cervenak L; Makó V; Gombos T; Udvardy ML; Hársfalvi J; Prohászka Z
Thromb Haemost; 2009 Feb; 101(2):305-11. PubMed ID: 19190814
[TBL] [Abstract][Full Text] [Related]
5. Serial changes in von Willebrand factor-cleaving protease (ADAMTS13) and prognosis after acute myocardial infarction.
Matsukawa M; Kaikita K; Soejima K; Fuchigami S; Nakamura Y; Honda T; Tsujita K; Nagayoshi Y; Kojima S; Shimomura H; Sugiyama S; Fujimoto K; Yoshimura M; Nakagaki T; Ogawa H
Am J Cardiol; 2007 Sep; 100(5):758-63. PubMed ID: 17719316
[TBL] [Abstract][Full Text] [Related]
6. Neutrophil Protease Cleavage of Von Willebrand Factor in Glomeruli - An Anti-thrombotic Mechanism in the Kidney.
Tati R; Kristoffersson AC; Manea Hedström M; Mörgelin M; Wieslander J; van Kooten C; Karpman D
EBioMedicine; 2017 Feb; 16():302-311. PubMed ID: 28139439
[TBL] [Abstract][Full Text] [Related]
7. C2362F mutation gives rise to an ADAMTS13-resistant von Willebrand factor.
Casonato A; Pontara E; Battiston M; Morpurgo M; Cattini MG; Casarin E; Saga G; Daidone V; De Marco L
Thromb Haemost; 2013 Jun; 109(6):999-1006. PubMed ID: 23446343
[TBL] [Abstract][Full Text] [Related]
8. ADAMTS13 activity is decreased in a septic porcine model. Significance for glomerular thrombus deposition.
Bockmeyer CL; Reuken PA; Simon TP; Budde U; Lösche W; Bauer M; Birschmann I; Becker JU; Marx G; Claus RA
Thromb Haemost; 2011 Jan; 105(1):145-53. PubMed ID: 21057705
[TBL] [Abstract][Full Text] [Related]
9. Significance of plasma von Willebrand factor level and von Willebrand factor-cleaving protease activity in patients with chronic renal diseases.
Lu GY; Shen L; Wang ZY; Guo XF; Bai X; Su J; Ruan CG
Chin Med J (Engl); 2008 Jan; 121(2):133-6. PubMed ID: 18272039
[TBL] [Abstract][Full Text] [Related]
10. Are increased levels of von Willebrand factor in chronic coronary heart disease caused by decrease in von Willebrand factor cleaving protease activity? A study by an immunoassay with antibody against intact bond 842Tyr-843Met of the von Willebrand factor protein.
He S; Cao H; Magnusson CG; Eriksson-Berg M; Mehrkash M; Schenck-Gustafsson K; Blombäck M
Thromb Res; 2001 Aug; 103(3):241-8. PubMed ID: 11672586
[TBL] [Abstract][Full Text] [Related]
11. The p.R1819_C1948delinsS mutation makes von Willebrand factor ADAMTS13-resistant and reduces its collagen-binding capacity.
Daidone V; Saga G; Barbon G; Pontara E; Cattini MG; Morpurgo M; Zanotti G; Casonato A
Br J Haematol; 2015 Aug; 170(4):564-73. PubMed ID: 25904363
[TBL] [Abstract][Full Text] [Related]
12. Plasma levels of active Von Willebrand factor are increased in patients with first ST-segment elevation myocardial infarction: a multicenter and multiethnic study.
Rutten B; Maseri A; Cianflone D; Laricchia A; Cristell NA; Durante A; Spartera M; Ancona F; Limite L; Hu D; Li H; Uren NG; de Groot PG; Mannucci PM; Roest M
Eur Heart J Acute Cardiovasc Care; 2015 Feb; 4(1):64-74. PubMed ID: 24833640
[TBL] [Abstract][Full Text] [Related]
13. Prognostic value of plasma von Willebrand factor and its cleaving protease ADAMTS13 in patients with atrial fibrillation.
Freynhofer MK; Gruber SC; Bruno V; Höchtl T; Farhan S; Zaller V; Wojta J; Huber K
Int J Cardiol; 2013 Sep; 168(1):317-25. PubMed ID: 23041092
[TBL] [Abstract][Full Text] [Related]
14. ADAMTS13 deficiency with elevated levels of ultra-large and active von Willebrand factor in P. falciparum and P. vivax malaria.
de Mast Q; Groot E; Asih PB; Syafruddin D; Oosting M; Sebastian S; Ferwerda B; Netea MG; de Groot PG; van der Ven AJ; Fijnheer R
Am J Trop Med Hyg; 2009 Mar; 80(3):492-8. PubMed ID: 19270304
[TBL] [Abstract][Full Text] [Related]
15. An unbalance between von Willebrand factor and ADAMTS13 in acute liver failure: implications for hemostasis and clinical outcome.
Hugenholtz GC; Adelmeijer J; Meijers JC; Porte RJ; Stravitz RT; Lisman T
Hepatology; 2013 Aug; 58(2):752-61. PubMed ID: 23468040
[TBL] [Abstract][Full Text] [Related]
16. Altered von Willebrand factor subunit proteolysis and multimer processing associated with the Cys2362Phe mutation in the B2 domain.
Casonato A; De Marco L; Gallinaro L; Sztukowska M; Mazzuccato M; Battiston M; Pagnan A; Ruggeri ZM
Thromb Haemost; 2007 Apr; 97(4):527-33. PubMed ID: 17393013
[TBL] [Abstract][Full Text] [Related]
17. A randomised pilot trial of the anti-von Willebrand factor aptamer ARC1779 in patients with type 2b von Willebrand disease.
Jilma B; Paulinska P; Jilma-Stohlawetz P; Gilbert JC; Hutabarat R; Knöbl P
Thromb Haemost; 2010 Sep; 104(3):563-70. PubMed ID: 20589313
[TBL] [Abstract][Full Text] [Related]
18. Prospective study on the behaviour of the metalloprotease ADAMTS13 and of von Willebrand factor after bone marrow transplantation.
Peyvandi F; Siboni SM; Lambertenghi Deliliers D; Lavoretano S; De Fazio N; Moroni B; Lambertenghi Deliliers G; Mannuccio Mannucci P
Br J Haematol; 2006 Jul; 134(2):187-95. PubMed ID: 16846477
[TBL] [Abstract][Full Text] [Related]
19. Acute activation of the endothelium results in increased levels of active von Willebrand factor in hemolysis, elevated liver enzymes and low platelets (HELLP) syndrome.
Hulstein JJ; van Runnard Heimel PJ; Franx A; Lenting PJ; Bruinse HW; Silence K; de Groot PG; Fijnheer R
J Thromb Haemost; 2006 Dec; 4(12):2569-75. PubMed ID: 16968329
[TBL] [Abstract][Full Text] [Related]
20. Linear relationship between ADAMTS13 activity and platelet dynamics even before severe thrombocytopenia.
Song J; Lee KA; Park TS; Park R; Choi JR
Ann Clin Lab Sci; 2008; 38(4):368-75. PubMed ID: 18988930
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
